Proceedings of the National Academy of Sciences · 2000 · 180 citations · 45 references
PharmacyMedicinal ChemistryMolecular BiologyDrug DesignDrug DiscoveryStructural BiologyHit-to-lead OptimizationLead Compound DesignLead DiscoveryPrion Protein MisfoldingPrion Protein StructurePrion ReplicationCellular Prion Protein StructureDominant Negative EffectsIsoform IdentificationPrion Protein ConformationPrion Protein Domain ArchitectureStructural Polymorphism Of Prions
Recent structural insights into PrP C and its auxiliary molecules enable a more rational design of therapeutics against prion replication. The study aims to discover lead compounds that emulate dominant‑negative PrP C mutants to block PrP Sc formation. Using the Available Chemicals Directory, the authors computationally screened for molecules mimicking residues 168, 172, 215, and 219 of PrP C, visually evaluated 1,000 candidates, and tested 63 in scrapie‑infected mouse neuroblastoma cells. Two compounds, Cp‑60 and Cp‑62, dose‑dependently inhibited PrP Sc formation with low toxicity, and related analogues showed similar activity, suggesting this strategy could broadly target harmful protein–protein interactions.
Recent progress determining the structure of the host-encoded prion protein (PrP C ) and the role of auxiliary molecules in prion replication permits a more rational approach in the development of therapeutic interventions. Our objective is to identify a new class of lead compounds that mimic the dominant negative PrP C mutants, which inhibit an abnormal isoform (PrP Sc ) formation. A computational search was conducted on the Available Chemicals Directory for molecules that mimic both the spatial orientation and basic polymorphism of PrP residues 168, 172, 215, and 219, which confer dominant negative inhibition. The search revealed 1,000 potential candidates that were visually analyzed with respect to the structure of this four-residue epitope on PrP C . Sixty-three compounds were tested for inhibition of PrP Sc formation in scrapie-infected mouse neuroblastoma cells (ScN2a). Two compounds, Cp-60 (2-amino-6-[(2-aminophenyl)thio]-4-(2-furyl)pyridine-3,5-dicarbonitrile) and Cp-62 ( N ′1-({5-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-2-furyl}carbonyl)-4 methoxybenzene-1-sulfonohydrazide), inhibited PrP Sc formation in a dose-dependent manner and demonstrated low levels of toxicity. A substructure search of the Available Chemicals Directory based on Cp-60 identified five related molecules, three of which exhibited activities comparable to Cp-60. Mimicking dominant negative inhibition in the design of drugs that inhibit prion replication may provide a more general approach to developing therapeutics for deleterious protein–protein interactions.
45
Novel Proteinaceous Infectious Particles Cause Scrapie
Stanley B. Prusiner · Science · 1982 · 5.1K citations
Veterinary Medicine, Infectious Diseases, Molecular Biology +10
A new variant of Creutzfeldt-Jakob disease in the UK
Robert Will, James W. Ironside, Martin Zeidler et al. · The Lancet · 1996 · 2.7K citations
An Algorithm for Subgraph Isomorphism
J. R. Ullmann · Journal of the ACM · 1976 · 2.3K citations · Full text
Mice devoid of PrP are resistant to scrapie
Hansruedi Büeler, Adriano Aguzzi, Andreas W. Sailer et al. · Cell · 1993 · 2.1K citations · Full text